- NewsCategory：
- All Company news Industry news
common83One result
-
0927
NeuCyte Licenses Promising Novel ≠←Compound for Treatment of Refractory Epile≠∞βpsy and Related Neurological Disor∑γ' ders
NeuCyte, Inc., an innoσεvative biotech compa¶ ✘ ny focused on developing novel treε€'atments for neurologic₽↑↓al disorders, today announced that it α↑™has entered into an exclusive license agreλ•ement with Trillium Therapeu✔σλtics to advance an u→₽♦↓ndisclosed preclinical compound with potential β≈utility in treating refλ₹₩εractory epilepsy in the form of Dravet syndrome×← and related disorders.The compound co→ ↑vered by this agreement has £"←δdemonstrated highly encouraging activ♥$§÷ity during studies conducte♦δ£d by the National Institute of Neurological ≥Disorders and Stroke (NINDS) Epilepsy Therapy Scr₹₽₹eening Program (ETSP). It •÷ demonstrates a superior safeεβΩty and anti-seizure efficacy profile®δ over NINDS benchmark anti-epileptiπ'c drugs (AEDs) in eleven an↓✘imal models. It has also demonstr γ₩↔ated broad efficacy in NIH ani¶♥mal studies for pharmaco-resistant epil∏¶epsy. As a result, this novel aφφ>÷gent has gained the prestigious NINDS Re ¶d Book status and been selected as a prom& ¶ising lead drug candidate."This comp®γound is an exceedingly promi₹♠β★sing antiseizure drug which, although in p±α∑reclinical development, is quite eff•£≈<icacious in a wide variety• of highly predictive seizure'<♠ models," said Roger J. Porter, MD, Adj™←unct Professor of Neurology at the University≠$• of Pennsylvania, former ®♠"Deputy Director of NINDS, fo↓→σrmer Chairman of the White Hᧀouse Committee on Brain and Behavioral Sc∞'↓γiences, and former President of American Epil♣® epsy Society. "It may p>₩✔•rove very effective for patie®÷nts with epilepsy." As a first-in-class compound ☆★with unique mechanism of action profiles, this dr ↓♦ug candidate is likely to have ac™↔♠tivity across a variety of ÷&₽indications. The favorable efficacy and safety prπ♥ofile has also been validated∑₽₽≠ by NeuCyte's proprietary in vi Ω×tro human iPSC-derived mγ₹≠odels."Epilepsy is the $φ∏₹fourth most common neurological d↓φ¶isease affecting more than 65 million peφ$♠ople of all ages worldwide. The compl✘πex and multifactorial natur"♦>e of the disorders makes treatment complicated≠©λβ and challenging. Up to 40% of newly d↕<&↔iagnosed epilepsy patients are res ♣λistant to current therapies which highlightsσ≥ε the urgent need to •develop first-in-class treatments," said↕"→ Jacqueline A. French, MD, Chief Medical aλαnd Innovation Officer of the Epilepsy≥✔®≥ Foundation and epileptologist in New Yorkσ© City. "It is very encouraging to see newφ×↔≈ developments and therape™ε¥utic candidates in this disease area."Under th"™e terms of the agreement, Trillium has£↕ granted NeuCyte exclusive, worldwide r♥ ♣ights to develop and commercializλ♥e the compound. "Neu☆'♠λCyte is committed to bringing breakthrough th♠ §erapies to epilepsy patientsλ↑↑ and believe that our advan₩≠tageous translational te&★₩chnology platform and ✔ CNS expertise enable us to optimally adva✔αnce such therapeutic can≈♥≥didates," said Tao Huan₽<×g, PhD, JD, President₩' and Chief Executive Officer of NeuCyte. "Th←α₹is licensing agreement allows us to expand ourσπ pipeline and advance our goal of meeting unm↕✔et clinical needs and truly improving pat₽ ¶ient care and quality of life."inform ™↔ation source:pharma focus AsiaThe or""§♣iginal link:https:https:https://www.pharmafocusa&& ≥sia.com/news/neucyte-licenses-promisin↕♦g-novel-compound-for-treatment-ε↔of-refractory-epilepsy-and-related-neurological-d ↑×→isorders2019 Asia-pacific ♣π↑←pharma IP Leader Summit:ht♦₽σ tp://en.zenseegroup.com/p/510934/will be✔$↕Ω held in Beijing oπ ÷n November 14-15, and ©×will attract more than 500 industr✔β±←y experts from domestic and foreign'β £ pharmaceutical companies, biotechnolog↔&y companies, governments, as¶↓sociations, law firms, intellectual property ag↓•₹¶ents and other compa♦₽α→nies to attend.Official registrationδ and consultation chann₩↑§®els:Contact：AnnPhone: 021-65650305Email：Mark≠≠φeting@zenseegroup.comht tp://en.zenseegroup.co×≥m/p/510934/ -
0926
Ivy Brain Tumor Center and Br∏βidgeBio Subsidiary QED Therapeutics Announ<∏σce Collaboration to Advance Cancer₽✘∞ Research and Treatment Options
The Ivy Brain Tumor Center at Barroσ♥"w Neurological Institute, today announce€✘↔εd a new collaboration with∑®→ QED Therapeutics, In₽₹c., a subsidiary of Bri±¥dgeBio Pharma, Inc., (Na★↔¥sdaq:BBIO) to investigate the FGFR1-€↓$≤3 tyrosine kinase inhibitor, infigratinib, for tβ♥&₽he treatment of glioblastoma (GBM). With t"♥×₩he goal of addressin✔≈ ÷g unmet medical needs for÷'÷ those affected by malignant brain cancer, tλ ♦his collaboration will focus o±∑$>n targeting FGFR (fibrobl¥ ₽♣ast growth factor recepto££αr) genetic alterations t♣÷"≈hat have been shown to spur growth in maligna↓"✔nt tumors.“Five to seven p≈ •♣ercent of glioblastoma patient∞✘s’ tumors are driven by∞♠¶♦ FGFR signaling,” sai≠©d Dr. Nader Sanai, director of the Ivy Br™$ain Tumor Center. “We believe our collaboratio≤n with QED Therapeutics will ena©↓♦ble us to test how FGFR-drive÷γ•εn GBM tumors respond to in σfigratinib. If proven effective, we then int♠₩end to move forward new combined dr≤λ•ug strategies incorporating this target.”In the ™δpreclinical studies, the ★×"Ivy Center will employ orthotopically imπ×♥ planted, well-characterized✘± FGFR3 fusion patient-$derived xenograft models. This is intended to al♦₹☆λlow the team to further explore the extent t<§∑o which the drug crosses the blood-brainφ✔ε barrier and what activity it has in the brain.“Ω&→We believe the work we are undertaking with the I vy Center will provide critσ★✔↕ical insight to shape our clinical developmen★₩<t strategy for this disease,“ saidε•♦♥ Susan Moran, M.D., M.S.C.E., chief medical offi↔♦cer of QED Therapeutics. “Our hope is tha∞≈t infigratinib will beco₽$↑♥me the backbone of new combination therap ↔✘♦ies to treat patients with glioblast×βoma.”Infigratinib is an ora×Ωlly administered, FGFR1-3 se↕&↑<lective tyrosine kina ∞Ωse inhibitor. QED Therapeutiγε×cs has observed activit₽y that appears to be meaningful in clinica©♦l trials for cancers that are dr↑♣γ"iven by errors in the FGFR genes. Thes ✔™βe include chemotherapy-refrac♠↓®♦tory cholangiocarcinomaβ§ with FGFR2 fusions and advanced™£< urothelial carcinoma with FGFR3 genλ↕₽etic alterations.“Th ₽e intricacies of the brain have posed s≠ ∏ignificant challenges for ↓γσbrain cancer research and the deve↓≈♥lopment of therapies,” said₹ Gary Li, head of translational medicine at QED ←↕∏™Therapeutics. “We believe collaborating± with the Ivy Brain Tumor Ceβ ×≤nter will enable us to move swiftly and§☆∞< further translational research that©∞ we hope will unlock the doors to effective treβ¶γatment options.”information source:pharma fo÷♣Ωλcus AsiaThe original link:https:https:/∞ε /www.pharmafocusasia.com/news/iv≤δ₩y-brain-tumor-center-and-b€×§€ridgebio-subsidiary-qed-therapeutics-announce§←>-collaboration-to-advance-σβ™≥cancer-research-and-treatment-options2019 Aε≠↓φsia-pacific pharma IP L₹λσ™eader Summit:http://en.zenseegroup.com/p/51π≤↔0934/will be held in Beβ←↑ijing on&σ∑ nbsp;November 14-15, and will attract δ♣more than 500 industry experts fro&βm domestic and foreign pharmaceutical companiβ€≠es, biotechnology companies, ♣>®governments, associa& ↕tions, law firms, intel€₽☆lectual property agents ↔'↓and other companies to attend.Offic→φ€ial registration and consultation channels:C✔♠★♣ontact：AnnPhone: 021-65650305Email：Marketing@zen₩¶↕♣seegroup.comhttp://www.zenseegro" ₩∞up.com/forms/view/22113/ -
0925
I-Mab Biopharma Announces Clinical Collaborati∞♥on to Evaluate TJC4 in Combinat φion with KEYTRUDA® (pembrolizumab)
I-Mab Biopharma ("I-Mab"), a China and U.S.-based λ clinical stage biopharmaceutical company λexclusively focusing on ±&δthe discovery and development of pφΩ&×otential first-in-class♥₩•♣ and best-in-class biologics in immuno-on♣≤cology and autoimmune diseases, today announced'∏ ¥ that it has entered into a clinical resea→€"rch collaboration agree≠✔γΩment with MSD, a tradename of>≥ Merck & Co., Inc., K₹αenilworth, NJ., USA, σ→ to evaluate the comb€ φination of I-Mab's TJC4 and MS∑§ D's anti-PD-1 therapy, KEY↕₩TRUDA® (pembrolizuma≠≤b) in patients with multiple canc₩er types.Under this collaboration agreement, MSβ≠α✘D will supply KEYTRUDA®☆&₹ (pembrolizumab) to I-Mab f≈ >₹or use in clinical studies in com☆Ω♠bination with TJC4, a fully human an↕★✔ti-CD47 monoclonal antibo↑∞dy. Both parties will collaborat≥£e on a Phase 1 clinical trial, based on±¶ an agreed and finalized p₹¶ ↓rotocol, to evaluate the sa"↓↓fety, pharmacokinetics, pharma↕εcodynamics and preliminary efficacy of TJC4 and ®→ KEYTRUDA® in patients with multiple cancer ↔↕types."TJC4 is a highly differα↔entiated anti-CD47 antibody currently undδ∏'er clinical developmenσ×t. This collaboration will pπ®≠rovide an excellent opportunity to further explor¥∑e therapeutic potential of combining TJC4 ♠¥ with KEYTRUDA® across₩→β different tumor types." said Dr. ₽∞σ¥Jingwu Zang, Founder and Chairman of I-Mab∑≠→.KEYTRUDA® is a registered trademark of ★γ♠≈Merck Sharp & Dohme Corp., a subsidiary δ↕÷&of Merck & Co., Inc., Kenilworth, N λ∑'J, USA.information source:pharma foc↔≠×¥us AsiaThe original link:https://www."♦εγpharmafocusasia.com/news/i-mab-biophar✔♣'ma-announces-clinical-collaboration-to-e←valuate-tjc4-in-combination-with-key↕✔>♦truda2019 Asia-pacific pharma IP Leader Summit→←∞•:http://en.zenseegroup.com/p∞♠ $/510934/ will be held in B©±eijing on November 14-15, and&"φ™ will attract more than 500 industry expe≥δ♣πrts from domestic and fo♦←reign pharmaceutical companies, ↕®×biotechnology companies, govern∞¥ments, associations, law firms, intellectua&✔l property agents and other com± ™panies to attend.Official registration and consulΩ♥¶γtation channels:Conta'π ≠ct：AnnPhone: 021-65650305Email：Marketing@♣←★zenseegroup.comhttp://www♥♦×.zenseegroup.com/forms/view/22113/ -
0923
Boehringer Ingelheim ↕♥§Partners with Inflammasome Therapeu&™tics to Develop Novel Therapies for Patien ♠'ts with Retinal Diseases
Boehringer Ingelheim and Infl€Ω>ammasome Therapeutics Inc. (Inflammasome) toda≠y announced they have entere ™≥&d into a co-development and lice©☆nse agreement to develop up to☆≤α✔ three therapies for patients with retinaαφl diseases. By combining Inflammas≥★ome’s unique intravitreal (IV$®T) drug delivery technologies with Boehringer♠↑ Ingelheim’s compounds from its retinal ♦∑₩✔disease pipeline portfolio, Boehringe¥¶r Ingelheim aims to deβ✘velop novel therapies for retin↑♦€∞al diseases.In 2019 there were ♦±an estimated 82 million patie₹α₩nts in the seven key cβ© ≥ountries (U.S., Japan, Gφγ×ermany, U.K., Spain, Italy, France★≤) affected by one of the δ₽≠three major forms of retinal disease: Age rela₩ ↕ted macular degeneration (AMD), diabetic ©"retinopathy (DR), and diab"ε<etic macular edema (Dπ§ME). Globally, the prevalence r≤≈σates of these and other retinal diseases are ex↕£★®pected to increase over the nextπ≤ 10 years primarily due to agin×φ∑g populations and the global diabetes epidem₹εic. Despite therapeutic advances in±≥✘≠ some disease areas durin→>♦g the past years, the real worl∏¥d results are poor, and ther¥ ♥↓e are no or only limited treatment op tions in many areas, resulting in an o∞♥∑verall high unmet need. The collabor™βation between Boehri§≠±nger Ingelheim and Inflammasome aims to address & π§this challenge by using I®∞nflammasome’s technology to deliver tε₩™herapeutics in a biodegradable gel formulation i¶nto the eye.“We are ↑"≠delighted to enter into a collabora≠tion with a company of BoehriΩ✔λ>nger Ingelheim’s stature,” said Paul Ashton, &÷©Chief Executive Officer of Inflam±±♦masome Therapeutics. “γ∏€₹We look forward to working wit ₽¶h their team to leverage our respective technolo☆ααgies and expertise to develop new therapiesβ∏♦¥ for devastating retinal dis→α eases leading to blindness. This collaborati "on fits our strategy of advanci≈✘♥☆ng the company via both collabor↓£ations and internal development.”“Boehring→ ¶•er Ingelheim is looking forward to develop↑↓≈ing Inflammasome’s novel technology for t€♠εhe delivery of our first-in- class reti₩Ω©nal disease compounds working jointly with Infla₹≈₽σmmasome’s highly experienced scientific t€β♠→eam,” said Clive R. Wood, PhD, Seniorδ₹≥ Corporate Vice Presσ∑ident, Discovery Research at Boehrin✘"®∑ger Ingelheim. “Thisλ€ will enable us to develop ↔εγa broad range of novel therapy options for thδ☆<e many patients with retinal diseases waiti∞∑ng urgently for better δ•₩®and new therapy options.”Boehringer Ing<≤elheim takes a holistic approac≈±h in the development of novelαα retinal disease therapies, targetin↕®☆g key mechanisms in the pathogenesis of ret≤✔inal diseases. The company ππhas built a comprehensive p$♣ipeline portfolio of next genφε↕↔eration therapy approaches in various stages of§₩↓ development up to Phase 2 in ×↔macular degeneration, diabetiε¶c retinal diseases and beyond. Inflammasome’s Ω♥¶✘novel delivery technology αusing a long-acting degr ÷&×adable IVT implant complements this portfolio✔βδ→.Inflammasome is entitled to receive up to £§↑$160 million in up-front, research and deve≠γ÷lopment support and mi♥×φlestone gated development payments as we× γll as tiered royalties based on fσ•uture commercial sales of developed produc ÷™ts and other milestones due on commercializatio™₹'n.information source:pharma focγ∏→βus AsiaThe original link:https://www.pharm↕δδ≈afocusasia.com/news/boehringer-ingel•"₽heim-partners-with-inflammasome-t¥€herapeutics-to-develop-n♥✔£ovel-therapies-for-patients→∞-with-retinal-diseases2019 Asia-pacific∏£ pharma IP Leader Summit: ht§✔→&tp://en.zenseegroup.com/p/510934/wi∑"₽ll be held in Beijing&←"≈nbsp; on November 14-15, and will attra>γct more than 500 industry expertδαs from domestic and foreignᥧ pharmaceutical compani☆ ¥es, biotechnology companies, ≥φ&πgovernments, associations, law firms, intelle≠∑→ctual property agents and other coδ∞>mpanies to attend.Official registration≥→ and consultation channels:Contact：AnnPhone: ₩¶£021-65650305Email：Marketing@zenseegr™±♣♣oup.comhttp://www.zenseegroup.♥§♣com/forms/view/22113/ -
0920
Clene Nanomedicine, Inc. Announces Selection oε•'δf CNM-Au8 for the Harvard Led HEALEY ALS Platλ©× form Trial, a Clinical Trial fo≠↔≥r Amyotrophic Lateral Sclerosis÷♦γ
Clene Nanomedicine, Inc.→σ, a clinical-stage biopharmaceu₽©≤®tical company, announced tod>Ω 'ay that the Sean M. Healey & AMG CΩ€¥≈enter for ALS at Mass General has select©ε$→ed CNM-Au8 for inclusion in the first→ § ever Platform Trial for the treatment ∞λof amyotrophic lateral sclerosis (ALS).The Heal ₹&ey Center issued a call earlier this year for th©φe best therapeutic candidates to $✔εapply for entry into theσ<☆ HEALEY ALS Platform Trial. Th←÷π≈ey received responses from nearly 30 applican"←₹ts across ten countries. Members from ↔ the Healey Center Science Advisory Comm€∞∑φittee, a group of renowned ≠ALS scientists, chose the top five therapeu®γΩ tic candidates, including Clene's lead ✔γclinical asset, CNM-Au8. The selectio©↑>n of CNM-Au8 into the Heale ↓y ALS Platform Trial≥≠ includes substantial financial s≠£≈upport and provides access to over♥≈ 50 expert ALS clinical tr↓♣ial sites across the United States."Our goal,₩<φ" said Merit Cudkowicz, MD, MSc, D★₹φirector of the Healey Center, "isπ& to lower the barriers for our pharma a←$nd academic colleagues to bring their £γexciting therapies for ALS fα→ε'orward to clinical trials. ♥©We are determined to accelerateσ↑• therapy development for ALS."Important p∑>reclinical work supporting the effort w±αith CNM-Au8 was performed in the lαφ♣×aboratory of Nicholas J. Marag∞¶↔akis, Director of the ALS Center for Cell εδ§$Therapy and Regeneration Research at ♠α→Johns Hopkins, using human induced plurip<©✘otent stem cells from ALγS patients. Dr. Maragakis is Chair of Cle →"ne's Scientific Advisory B∏↑oard for ALS.Dr. Jonathan Glass, Professor₩§✘ of Neurology and Pathology at Emory University ₽γ"School of Medicine, as well as Direct♦φor of the Emory ALS Center,✔∑ remarked, "CNM-Au8 is quite♣✘↔ an interesting compound that is re©'ady for testing in ALS clini♣λ€cal trials. Its inclusiσ♠on in the Platform Trial initiative is an ≤↔®excellent way to move forward ₹¥for the development of CNM-Au8 as a potentia±<×l therapeutic for ALS.""We are ver♣ ♦y pleased Clene's CNM-Au8 has been sel€↓ected for participation in the Healey ALS P•>"♠latform Trial. We believe the unique mechanism o"↑×↔f CNM-Au8 represents a promising new approaφ≥±§ch for the treatment of neurodegenerative d↔Ωiseases, including ALS, with the potential f≠ £®or meaningful impact for≤÷ the community of people dia✔¥• gnosed with this devastating Ωγ£and debilitating disease," saidπε Rob Etherington, Presidenוt and CEO of Clene. "We are contin♦♠uing the development of CNM-Au8 in several clini∞σcal studies set to launch later this ≥φ®♥year."2019 Asia-pacific pharma✔≠¥ IP Leader Summit: http://en.zenseegroup.com±♠≠/p/510934/will be held in B↔÷¶δeijing on November 14-15 ♥, and will attract more tha♠₹Ω↓n 500 industry experts from domesti& ≥c and foreign pharmaΩ€✔ceutical companies, bio÷™∏>technology companies, governments≠✘¥, associations, law firms, intelφπlectual property agents and other companies to©>☆® attend.Official registration and ≤±consultation channels:Contact：AnnPhone: 02™σ →1-65650305Email：Marketing@zenseegroup.comhttp∏'λΩ:/forms/view/22113/≈σ£ε
Contact Us
Zensee_Daystar online
© 2011-2016